Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
NCT00595686
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Hematologic Neoplasms
Interventions
DRUG:
SNX-5422
Sponsor
Esanex Inc.
Collaborators
[object Object]